4D Molecular’s Legal Chief Buys Low, Sells Options as Stock Races Toward 52‑Week High.

Insider Activity Highlights the Momentum Behind 4D Molecular’s Stock Rally

4D Molecular Therapeutics (NASDAQ: 4DM) closed the week on $12.69, up 12.9% on the day and more than 40% on the month. The company’s 52‑week high of $14 is now within reach, and the market cap is just over $663 million. Amid this bullish backdrop, Chief Legal Officer Bizily Scott executed a series of transactions that underline both confidence in the company’s prospects and the tactical use of the company’s 10b‑5 trading plan.

Buy‑side Activity Signals Insider Optimism

On June 30th, Scott purchased 814 shares at $4.14 and 5,752 shares at $6.49, a total of 6,566 shares. These purchases were executed under the 10b‑5 trading plan adopted on January 13, 2026, which provides a disciplined framework for insider buying. The fact that the trades were priced below the day’s closing price ($12.69) indicates that Scott is buying at a discount, perhaps as part of a systematic accumulation strategy rather than a short‑term market play. The timing also coincides with a significant uptick in the company’s share price, suggesting that insiders are keen to capitalize on the momentum.

Selling of Options Reflects Strategic Realization

In contrast to the shares, Scott sold a block of stock options for 6,566 shares at a strike of $14, and an additional 5,752 shares at $0 strike (i.e., exercised options). The option sales bring in proceeds while simultaneously reducing the potential dilution from future option grants. Historically, Scott has frequently exercised options and sold the resulting shares—most recently in March 2025 when 217,000 options were exercised—and the pattern shows a deliberate approach to convert option holdings into cash when the stock price rises.

What This Means for Investors

• Liquidity and Confidence: The combination of buying and option selling demonstrates that insiders are comfortable with the current valuation and expect the price to remain solid.
• Potential for Future Moves: The use of a 10b‑5 plan and ongoing option exercise suggest that additional insider transactions could occur as the company meets milestones or as new options vest.
• Market Sentiment: The neutral sentiment score (-0) and low buzz (0%) imply that the market is not yet reacting strongly to the insider activity, which could create an opportunity for investors looking to enter before any subsequent moves.

Bizily Scott: A Profile of a Calculated Insider

Scott has been a prolific buyer and seller of 4D Molecular shares over the past 18 months. In 2025 alone, he executed multiple trades that ranged from buying at $4.14 to selling at $12.00, with a pattern of buying when the stock dips and selling when it climbs. He also holds a sizable block of unvested options—over 60,000 shares—highlighting his long‑term commitment to the company. As Chief Legal Officer, Scott’s transactions are closely monitored by the market; his disciplined use of a trading plan and consistent option exercises signal a strategy grounded in legal compliance and fiscal prudence.

Investor Takeaway

Insider activity from a senior executive like Bizily Scott is a useful gauge of confidence. The current buy/sell mix suggests that he believes the stock is undervalued at present but also wants to lock in gains from recent upside. For investors, this presents a potential entry point: the shares are trading near the lower end of a 52‑week range that has already delivered a 229% yearly gain, and insider buying under a 10b‑5 plan may presage further institutional support. As always, monitoring future trades and the company’s clinical milestones will be key to assessing whether 4D Molecular can sustain its upward trajectory.